Article

Mechanism of Action of PARP Inhibitors

2024-12-03

Abstract excerpt

The selective vulnerability of BRCA1/2- mutated ( BRCA mut ) cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors provides one of the best examples of synthetic lethality that has been translated into the clinic. The success of this approach has led to a paradigm shift, with four PARP inhibitors now approved by the US Food and Drug Administration (FDA) for the treatment of ovarian, breast, prostate, and/o...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 84b09180-329c-5b54-91ad-1feb9e281da5
DOI: 10.1146/annurev-cancerbio-042324-103725

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mechanism of Action of PARP InhibitorsDOI 10.1146/annurev-cancerbio-042324-103725Read

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor ResistanceSemantic proximity Read

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targetingSemantic proximity Read

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP InhibitorsSemantic proximity Read

The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host InteractionsSemantic proximity Read

PARP Inhibitors in Breast and Ovarian CancerSemantic proximity Read

PARP inhibitorsSemantic proximity Read

Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase InhibitorsSemantic proximity Read

An update on PARP inhibitors for the treatment of cancerSemantic proximity Read

Poly (ADP-ribose) polymerase inhibitors in cancer therapySemantic proximity Read

[Cancer therapy by PARP inhibitors].Semantic proximity Read

Strategies for the prevention or reversal of PARP inhibitor resistance.Semantic proximity Read

PARP inhibitors in cancer therapy: an updateSemantic proximity Read